Q-omics provides the consensus-scored CDC14A profile across patient tissues and cancer cell-line models. CDC14A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CDC14A is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, CDC14A RNA expression shows 20,954 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where CDC14A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDC14A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDC14A survival associations across molecular data types. CDC14A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDC14A RNA expression–survival associations across cancer types. High CDC14A expression shows unfavorable associations in LIHC and LGG, but favorable associations in KIRC, BRCA, SKCM and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CDC14A RNA expression.
This table summarizes CDC14A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CDC14A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDC14A shows lower tumor expression in COAD, KIRP, LUAD, LUSC, KIRC and BRCA. The COAD box plot shows higher CDC14A RNA expression in normal versus tumor tissue (log2 FC = −1.721, t-test p < 0.001).
This table shows molecular features associated with CDC14A in patient tissues and cancer cell lines. In patient samples, CDC14A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CDC14A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
